StoryManufacturing
Life Biosciences and Forge Biologics sign a clinical-grade manufacturing deal for its gene therapies
Forge Biologics agreed to provide GMP manufacturing, process development, and analytical services for Life Biosciences' AAV gene therapy platform. The partnership at Forge's 200,000-square-foot Columbus facility will focus on Life Biosciences' lead ophthalmic program targeting retinal ganglion cell dysfunction from partial epigenetic reprogramming.
- Forge will deliver AAV process development, toxicology, cGMP manufacturing and analytical services.
- Work takes place at Forge's 'Hearth' facility in Columbus, Ohio.
- Partnership accelerates speed and quality of manufacturing as Life Bio progresses toward first human trials.
- Life Bio's cellular rejuvenation platform targets aging-related diseases.